297 related articles for article (PubMed ID: 10942634)
1. Drug-resistant viral hepatitis.
Wright M; Main J; Thomas HC
J Infect; 2000 Jul; 41(1):1-4. PubMed ID: 10942634
[No Abstract] [Full Text] [Related]
2. Characteristics of and current treatment options for hepatitis B and hepatitis C.
Adams P
J Can Dent Assoc; 2000 Nov; 66(10):537. PubMed ID: 12584770
[No Abstract] [Full Text] [Related]
3. [Treatment of lamiduvine-resistant mutant chronic hepatitis B with interferon alpha].
Pariente A; Tachet A; Poveda JD
Gastroenterol Clin Biol; 2002 Nov; 26(11):1059-60. PubMed ID: 12483147
[No Abstract] [Full Text] [Related]
4. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation.
Van Bömmel F; Schernick A; Hopf U; Berg T
Gastroenterology; 2003 Feb; 124(2):586-7. PubMed ID: 12557178
[No Abstract] [Full Text] [Related]
5. [Effects of lamivudine and interferon-alpha combination therapy on chronic hepatitis B].
Tang Y; Chen G; Zheng R
Zhonghua Gan Zang Bing Za Zhi; 2002 Apr; 10(2):89. PubMed ID: 11983118
[No Abstract] [Full Text] [Related]
6. [Advance in clinical studies of the kinetics of hepatitis B virus].
Tang YT; Cao Q; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):75-7. PubMed ID: 20128981
[No Abstract] [Full Text] [Related]
7. [Lamivudine treatment consensus from relative experts].
Lamivudine Clinical Practice Group
Zhonghua Gan Zang Bing Za Zhi; 2002 Apr; 10(2):157-8. PubMed ID: 12108391
[No Abstract] [Full Text] [Related]
8. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation.
Seehofer D; Rayes N; Steinmüller T; Müller AR; Settmacher U; Neuhaus R; Radke C; Berg T; Hopf U; Neuhaus P
Liver Transpl; 2001 Nov; 7(11):976-82. PubMed ID: 11699034
[TBL] [Abstract][Full Text] [Related]
9. [Lamivudine resistance impedes hepatitis B therapy].
Eggers HJ
Fortschr Med; 1997 Apr; 115(12):5. PubMed ID: 9235306
[No Abstract] [Full Text] [Related]
10. [Future perspectives and strategies in managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
Bourlière M
Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S34-6. PubMed ID: 17075495
[No Abstract] [Full Text] [Related]
11. Opportunistic infections update.
Proj Inf Perspect; 1998 Dec; (26):5-6. PubMed ID: 11366497
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B.
Janssen HL; van Zonneveld M; Schalm SW
N Engl J Med; 2004 Jun; 350(26):2719-20. PubMed ID: 15215493
[No Abstract] [Full Text] [Related]
13. Designing a low-cost drug resistance database for viral hepatitis.
Kuiken C
Antivir Ther; 2010; 15(3 Pt B):517-20. PubMed ID: 20516573
[TBL] [Abstract][Full Text] [Related]
14. [HBeAg-negative chronic hepatitis].
Ibragimova MM; Krel' PE; Abdurakhmanov DT
Ter Arkh; 2004; 76(2):87-91. PubMed ID: 15106425
[No Abstract] [Full Text] [Related]
15. Hepatitis B and C viruses: molecular identification and targeted antiviral therapies.
Berenguer M; Wright TL
Proc Assoc Am Physicians; 1998; 110(2):98-112. PubMed ID: 9542765
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication.
van Bömmel F; Wünsche T; Schürmann D; Berg T
Hepatology; 2002 Aug; 36(2):507-8. PubMed ID: 12143063
[No Abstract] [Full Text] [Related]
17. [Lamivudine treatment for hepatitis B].
Lamivudine Clincal Practice Group
Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):425-8. PubMed ID: 15487066
[No Abstract] [Full Text] [Related]
18. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy.
Suzuki F; Tsubota A; Akuta N; Someya T; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Miyakawa Y; Kumada H
J Gastroenterol; 2002; 37(11):922-7. PubMed ID: 12483247
[TBL] [Abstract][Full Text] [Related]
19. Designing clinical development programs for anti-hepatitis B virus drugs.
Brown NA
Methods Mol Med; 2004; 96():499-537. PubMed ID: 14762289
[No Abstract] [Full Text] [Related]
20. [Drug therapy of hepatitis B and C].
Färkkilä M
Duodecim; 2003; 119(6):519-29. PubMed ID: 12708339
[No Abstract] [Full Text] [Related]
[Next] [New Search]
